WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 08/02/21

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate PR Newswire SUZHOU, China , Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced ...

It was an excruciating week of a severe emotional storm with the share prices undergoing a rollercoaster ride. A deluge of news, speculations, and commentaries overwhelmed the mind. The massive and synchronized sell-off of Chinese equities was akin to a Golden Slam for the critics. It...

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility PR Newswire First GMP manufacturing authorization outside of China , validating WuXi Biologics' world-class quality system Only 12 month...

Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist f...

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments. At least one Chinese-made mRNA Covid vacci...

WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates PR Newswire WUXI, China and DAEJEON, South Korea, June 9, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company ded...

DualityBio last month announced securing an impressive $90 million in series B financing, with global giant Eli Lilly-backed Lilly Asia Ventures and Chinese heavyweight WuXi Biologics signing on as investors. ADCs combine monoclonal antibodies and a potent payload of drugs via a so-ca...

Key Chinese corporations have been under significant pressure lately. Concerns regarding Chinese government crackdowns, U.S. regulations, forced selling, and other factors have caused many shares to crater in recent weeks. However, a lot of the "issues" appear to be transitory and...

WuXi Biologics (WXXWY) has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90% interest of CMAB Biopharma Group ("CMAB").The transaction is expected to close...

WuXi Biologics (WXXWY) will acquire biologics manufacturing facilities in Hangzhou, China, from Pfizer China (PFE) in a deal expected to close in the first half of the year.Financial details were not disclosed.WuXi says the acquisition of the 50,000 square-meter facilities will allow the comp...